RareResearch.AI
← Back to atlas

D771H

Category 3/4 — Most DruggablePathogenicLumenal · predictedσ-1 candidateEditorial
AspartateHistidine at position 771 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Aspartate → Histidine at position 771 in wolframin's C-terminal lumenal domain. ClinVar Pathogenic. AlphaMissense 0.857, DynaMut2 ΔΔG -0.34 kcal/mol (destabilising). A charge-sign-change-plus-aromatic variant in a polar network position.

Interactive 3D Structure

Wild-type reference
Wild-type D771 — hydrogen bond to K768
Fullscreen ↗
DynaMut2 mutant · D771H
Mutant H771 — hydrogen bond to Y773 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost5 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Ionic bondE717Gained
Hydrogen bondI712Gained
Hydrogen bondN714N714Preserved
Hydrogen bondK768K768Preserved
Hydrogen bondY773Lost
Polar contactI712Gained
Polar contactN714N714Preserved
Polar contactK768K768Preserved
Polar contactY773Y773Preserved
Aromatic / πY773Gained
Van der WaalsN714Gained
Van der WaalsK768Lost
Van der WaalsY773Y773Preserved
HydrophobicI712I712Preserved
HydrophobicY773Y773Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.34kcal/mol
Destabilising — mild
AlphaMissense
0.857
LPath
AlphaFold pLDDT
88
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditions(no specific conditions catalogued for D771H — ClinVar Pathogenic by review evidence)
InheritanceInheritance not specified. ClinVar Pathogenic.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2311G>C
ClinVar accessionVCV001458820
Last evaluated2025/01/23 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Structural Context

Position 771 sits in wolframin's C-terminal lumenal domain. The AlphaFold model places D771 within 5 Å of ARG772 (2.4 Å — likely salt-bridge partner), PHE770 (2.5 Å), LYS768 (3.8 Å), ASP713 (3.8 Å — same residue cluster as N714T atlas card), and ASN714 (4.2 Å — direct N714 contact). The wild-type aspartate likely forms a salt bridge with R772 and contributes to the polar network involving N714 across the fold.

Replacing aspartate with histidine reverses the charge character: the lost negative charge eliminates the salt bridge with R772, and the introduced imidazole — neutral or protonated depending on local pH — cannot maintain the same electrostatic contribution. The ER lumen's mild acidity favors protonated histidine (positively charged), which would now repel R772 rather than attract it.

The N714 contact (4.2 Å) is the second key disruption: D771 and N714 are spatially close and likely form an H-bond. The new H771 is also a potential H-bonder but with different geometry; the network shifts.

The |ΔΔG| of 0.34 indicates fold absorbs the substitution. AlphaMissense's 0.857 score captures functional consequence — the disrupted R772 salt bridge and the perturbed N714 contact together signal severe pathogenic mechanism.

Amino-acid chemistry
Aspartate (D) → Histidine (H) — a small negatively-charged carboxylate-bearing residue replaced by a larger aromatic titratable basic residue. Charge sign reverses (negative to neutral/positive); aromatic character is added.
Position in the protein
C-terminal lumenal domain · position 771 in the ER lumen (pLDDT 88).

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.34 kcal/mol — fold survives. AlphaMissense 0.857 confirms pathogenic functional consequence.

The mechanism is loss of the D771-R772 salt bridge plus perturbation of the D771-N714 H-bond contact. Therapeutic strategy: site-directed at the D771-R772-N714 network. Combined with N714T (same network from the other side, atlas card adjacent), drug discovery has two convergent targets in this microregion.

Why this matters

D771H is the third Atlas variant in this batch that targets the D713-N714-D771-K768 polar network in the lumenal domain. The neighbor analysis surfaces this cluster as a recurring therapeutic target across multiple variants. A small molecule that stabilizes this polar network rescues several variants simultaneously.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the D771H PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download D771H PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal